Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAKs). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor, AZD1480, both as a single agent and in combination with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Suryani, Santi, Bracken, Lauryn S., Harvey, Richard C., Sia, Keith C.S., Carol, Hernan, Chen, I-Ming, Evans, Kathryn, Dietrich, Philipp A., Roberts, Kathryn G., Kurmasheva, Raushan T., Billups, Catherine A., Mullighan, Charles G., Willman, Cheryl L., Loh, Mignon L., Hunger, Stephen P., Houghton, Peter, Smith, Malcolm A., Lock, Richard B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326541/
https://ncbi.nlm.nih.gov/pubmed/25504635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0647
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados